Indolent lymphoma is class of cancer that grows and spread very slowly as compared to aggressive lymphomas.
Indolent lymphoma is class of cancer that grows and spread very slowly as compared to aggressive lymphomas. Indolent lymphoma originates in a part of the immune system of the body, known as lymphatic system, which comprises lymph nodes and lymphoid tissues, such as, the spleen and bone marrow. In this disease, white blood cells grow uncontrollably, interfering with the healthy blood cells that protect the body against diseases. Indolent lymphomas are usually not considered curable due to its characteristics, which make it very difficult to detect and target accurately even with modern treatment and diagnostic tools. About 80,000 cases of indolent lymphoma were diagnosed in the U.S. between 2006 and 2008. The disease is extremely heterogeneous in molecular nature and histology and exhibits major difference in incidences of the subtype in different geographical locations. According to Pfizer’s oncology factsheet, in 2008, approximately 355,900 cases of indolent lymphoma were diagnosed, leading to 191,400 deaths globally. Some of the factors responsible for indolent lymphoma are infections, obesity & age, and weak immune system. Treatment for indolent lymphoma depends on factors, such as, stage of the disease, age, family history, etc. Survival rate mainly depends on the stage of the disease.
Read Report Overview - https://www.transparencymarketresearch.com/indolent-lymphoma-market.html
Indolent lymphoma is more common in men than in women, especially the ones aged above 60 years. According to World Health Organization classification, the most common type of indolent lymphoma, accounting for almost 20% of malignant lymphomas in adults, is follicular lymphoma. In the U.S. and Western Europe, follicular lymphoma accounts for 40% of the total diagnosed cases of lymphoma. Suggested diagnostic modes for indolent lymphoma in the initial stages comprise computed tomography scan of the chest, abdomen, pelvis, and biopsy. Indolent lymphoma is often sensitive to initial treatment and responds favorably regarding patient survival for couple of years. However, in certain cases, it tends to reoccur and becomes resistant to treatment and may transform into aggressive lymphoma which is difficult to cure. According to the American Cancer Society, overall survival rate for indolent lymphoma falls in the range of 5 to 10 years. The 5 years relative survival rate of indolent lymphoma patient is approximately 63%, whereas, that of 10 years is around 51% in the U.S.
The global indolent lymphoma market is estimated to grow rapidly in the next few years. Key drivers of the market include rise in geriatric population and changes in lifestyle and habits. In present times, people have addictions, such as, drugs, alcohol, unhealthy food habits, etc. which are the main causes of various disorders. Biological therapies and chemotherapies have been extensively used to treat indolent lymphoma. Rapid technological advancements and wide acceptance of minimally invasive techniques are propelling the global indolent lymphoma market.
Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=50700
The global indolent lymphoma market can be classified based on product type, route of administration, distribution channel, and region. In terms of product type, the market can be segmented into DNA-damaging drugs, antitumor antibiotics, antimetabolites, protease inhibitor drugs, immunotherapy, and others. On the basis of route of administration, the market can be divided into parenteral, oral, and others. Based on distribution channel, the global indolent lymphoma market can be categorized into manufacturers, distributors, pharmacies, and others.
Request for Covid-19 Impact Analysis - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=50700
Geographically, the global indolent lymphoma market can be divided into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is anticipated to hold the major share of the global indolent lymphoma market due to technological advancements, well-developed better health care infrastructure, and favorable reimbursement policies in the region. The global indolent lymphoma market in Asia Pacific is estimated to grow significantly in the near future due to rapidly growing population, increase in investment in the health care sector by government and private bodies, and rise in per capita income.
Pre Book Indolent Lymphoma Market Report at - https://www.transparencymarketresearch.com/checkout.php?rep_id=50700<ype=S
The major companies involved in clinical trials of drugs against indolent lymphoma include F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc., GlaxoSmithKline plc, Sanofi, and Bayer AG.
More Trending Reports by Transparency Market Research:
Burkitt Lymphoma (BL) Therapeutics Market: Burkitt lymphoma, or small noncleaved cell lymphoma, is a highly aggressive B-cell non-Hodgkin lymphoma (NHL) characterized by the translocation and deregulation of the c-myc gene on chromosome 8. The 2016 World Health Organization (WHO) classification of lymphoid neoplasms recognizes Burkitt-like lymphoma with 11q aberration as a new provisional entity that lacks MYC rearrangements but resembles Burkitt lymphoma morphologically, to a large extent phenotypically, and by gene expression profiling.
Follicular Lymphoma Treatment Market: The medical term of Lymphoma refers to that specific type of cancer that attacks the lymphatic system of human body. Lymphoma badly affects the lymphocytes thereby leading to abnormal and rapid multiplication and growth of the cells of the immune system.. Lymphocytes refer to the cells of the human beings’ immune system.
About Us
Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.
Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.
Contact
Mr. Rohit Bhisey
Transparency Market Research
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: https://www.transparencymarketresearch.com/